BeOne Medicines Ltd.·4

Jul 22, 5:03 PM ET

OYLER JOHN 4

Research Summary

AI-generated summary

Updated

BeOne (ONC) CEO John Oyler Exercises Options and Sells Shares

What Happened
John Oyler, CEO of BeOne Medicines Ltd. (ONC), exercised stock derivative(s) and conducted a series of open-market sales on July 20–21, 2026. The filing shows he acquired 33,990 shares by exercising options at $119.96 per share (cost ≈ $4,077,440) and sold a total of 109,713 shares in multiple open‑market transactions at prices around $310–$320, producing aggregate proceeds of about $34.59 million. The filing also reports a separate derivative/convertive disposition of 441,870 shares showing $0 proceeds (reported as a derivative transaction).

Key Details

  • Transaction dates: primarily July 20–21, 2026; Form 4 filed July 22, 2026 (timely filing).
  • Option exercise: 33,990 shares acquired at $119.96 each (≈ $4,077,440).
  • Open-market sales: 109,713 shares sold in multiple blocks; weighted-average prices reported per block; total proceeds ≈ $34.59M.
  • Derivative disposition: 441,870 shares reported as disposed at $0 (no cash reported).
  • Notable footnotes: sales covered by a Rule 10b5‑1 trading plan (footnote F7); several sales reported as weighted-average prices spanning listed price ranges (footnotes F8–F21); each American Depositary Share (ADS) represents 13 ordinary shares (F6).
  • Ownership disclaimers: some securities are held in trusts/LLCs for which Oyler disclaims beneficial ownership (footnotes F1–F5).
  • Shares owned after these transactions: not specified in the provided excerpt of the filing.

Context

  • The filing shows an exercise of options followed by immediate open‑market sales on the same days, which effectively converted optioned shares into cash; the separate $0 derivative disposition indicates a non‑cash settlement or internal conversion reported by the filer (the filing does not explain the mechanics).
  • Sales under a 10b5‑1 plan are pre‑arranged and are commonly used to avoid questions about timing; the filing discloses this for at least some of the sales.
  • This is factual reporting of transactions only — it does not indicate the CEO’s reasons or signal company performance by itself.